Dr. Pautier on Challenges With Drug Development in Leiomyosarcoma

Patricia Pautier, MD, head of the Medical Day Hospital Unit at the Institut Gustave Roussy Cancer Campus, discusses limitations in leiomyosarcoma.

Leiomyosarcoma is a rare disease. As such, developing effective therapies continues to be a major challenge, says Pautier.

Historically, immunotherapy, whether used in combination with doxorubicin or alone, has not shown much activity in this patient population.

Similar to soft tissue sarcomas, oftentimes, uterine leiomyosarcomas will express hormonal receptors. As such, future research efforts should focus on adding targeted therapies to the armamentarium, Pautier concludes.